Medical, Dental, and Hospital Equipment and Supplies Merchant Wholesalers (NAICS 423450)

1. Overview

Every gown, glove, syringe, surgical kit, hospital bed, dental chair, and exam-room consumable used in American health care passes through a middle layer between the factory and the caregiver. NAICS code 423450 covers the merchant wholesalers — the distributors — who buy medical, dental, surgical, and hospital equipment and supplies, warehouse them, and resell them to hospitals, surgery centers, doctors' and dentists' offices, nursing homes, and increasingly to patients at home. They take title to the goods (they own the inventory), which is what makes them "merchant" wholesalers rather than agents or brokers.[1]

This is a large, essential, low-margin logistics business. In 2022 the industry booked about $311.5 billion in sales across roughly 7,394 firms.[2] It employed about 272,000 people at about 10,300 establishments in 2023.[3] Demand is tied to health care utilization rather than the economic cycle, which makes the sector defensive — people get sick and have surgery in recessions too — but the economics are unforgiving: distributors live on razor-thin spreads and win on scale, working-capital discipline, and logistics. About 90% of hospitals use commercial medical-supply distributors rather than self-distribution.[4]

Investors can reach this industry two ways. Public-market investors can buy a small set of listed distributors — most notably Medline (which went public in December 2025) and Henry Schein — plus the medical-distribution segments buried inside the big diversified health care companies (Cardinal Health, McKesson, Cencora). Private-market investors are, if anything, more central here: private equity now owns some of the biggest names in the space (Patterson, and the former Owens & Minor distribution business), and a large tail of regional and specialty distributors are family- or PE-owned.

2. What it is and how it's structured

Scope. NAICS 423450 is wholesale distribution of medical, dental, hospital, ophthalmic, laboratory, and surgical equipment and supplies — the physical products of care, from commodity consumables (gloves, gauze, sutures, needles) to capital equipment (imaging systems, dental chairs, patient monitors) and home medical equipment. The defining activity is distribution: buying, storing, and reselling goods, plus the services layered on top (delivery logistics, kitting, inventory management, financing, equipment service, and practice-management software).[1]

The merchant wholesaler normally buys or otherwise takes responsibility for inventory, aggregates products from many manufacturers, stores them in regional distribution centers, breaks cases into low-unit-of-measure deliveries, and handles ordering, invoicing, returns, recalls and data feeds. Large distributors also assemble procedure kits, manage hospital inventories, provide equipment service, and perform third-party logistics. The Health Industry Distributors Association (HIDA) reports its member network handles more than 1.4 million products from over 7,300 manufacturers through more than 500 distribution centers — those are association-member statistics, not a Census count of the full NAICS industry.[5]

Acute-care business is commonly awarded through "prime vendor" contracts. A hospital system or group purchasing organization negotiates product pricing with manufacturers, while the distributor is paid to source, hold and deliver the products. Some arrangements use cost-plus percentages, while others use activity-based fees tied to service complexity; in certain arrangements the distributor may not take title even though it retains custodial risk.[6]

What it excludes — this matters, because the boundaries are where the biggest companies actually sit:

• Pharmaceutical wholesaling is a different code: NAICS 424210 (Drugs and Druggists' Sundries Merchant Wholesalers). The famous "Big Three" drug distributors — McKesson, Cencora (formerly AmerisourceBergen), and Cardinal Health — book most of their revenue there, not in 423450. Only their medical-surgical product lines fall into this industry.[7]
• Making the devices is manufacturing, under NAICS 339112 (surgical/medical instruments), 339113 (surgical appliances/supplies), 339114 (dental equipment), and 339115 (ophthalmic goods). A company like Medline both manufactures and distributes, so part of its activity is technically a manufacturing code.
• Ophthalmic goods wholesaling (eyeglasses, contact lenses) has its own adjacent code, NAICS 423460.[1]
• Providing the care (hospitals, physician offices, home-health-care services) sits in the NAICS 62 health care sector, and retail pharmacies/drug stores are in 456110.

Ownership mix. The industry splits into a handful of national giants and a very long tail of small, often specialized distributors — regional med-surg houses, single-specialty distributors (orthopedics, wound care, laboratory), and local dental/veterinary suppliers. Federal concentration data confirm this shape: the top 4 firms hold only about 23.9% of revenue, the top 8 about 40.6%, the top 20 about 62.6%, and the top 50 about 75.7%.[2] The Herfindahl-Hirschman Index (HHI, a standard concentration measure where anything under 1,500 is considered unconcentrated) is just 273.9 for the industry as a whole.[2] That "fragmented" headline is real — but misleading, because the industry is really several distinct sub-markets, and some of those (hospital med-surg, dental) are near-oligopolies once you cut the data by channel.

3. How big it is

From our federal source data:

The ~$125,000 average payroll per worker is high for a wholesale/logistics industry, reflecting a big, well-paid sales force and technical/clinical support staff alongside warehouse labor. The Small Business Administration (SBA) sets the small-business cutoff for this industry at 200 employees, which is unusually generous and signals a business where scale matters.[8]

Undercount and boundary caveats. Unlike industries dominated by government or by tiny sole proprietors, wholesale distribution is captured reasonably well by the Economic Census, so the $311.5 billion figure is a solid measure of the equipment-and-supplies distribution slice specifically. A narrower HIDA/Clarivate panel tracked $57.5 billion of U.S. medical-supply distribution revenue in 2023 (representing about 85% of that defined channel), rising to $61 billion in 2025 — up 4.6% year over year.[9] These figures cover a narrower medical-supply channel and cannot be reconciled mechanically with the Census's much broader establishment receipts.

The nuance runs the other way for headline companies: the household-name companies are far bigger than the Census figure suggests because their totals span several NAICS codes. McKesson and Cardinal Health each report well over $150 billion in total revenue, but most of that is pharmaceuticals (424210); only their medical-surgical lines land here. Medline's ~$28.4 billion in 2025 sales spans both distribution (423450) and its own manufacturing (339xxx).[10] So read the $311.5 billion as the size of the activity, not the combined revenue of the companies that dominate the headlines.

4. The investable universe

There are only a handful of listed pure-play or near-pure-play distributors; most exposure comes through diversified health care companies or through private ownership. Scale figures below are recent annual revenue (company-wide unless noted); tickers and market values are for the how-to-invest discussion in Section 10.

Two things stand out. First, the dental channel is essentially a duopoly — Henry Schein and Patterson dominate U.S. dental distribution — and Patterson is now private, leaving Henry Schein as the main listed dental play. Second, the acute-care/hospital med-surg channel is an oligopoly of Medline, McKesson Medical-Surgical, Cardinal Health, and Concordance, into which Owens & Minor sold its distribution business in late 2025. For a "clean" public distributor, the shortest list is really Medline (new to public markets) and Henry Schein; everything else is either a segment inside a pharma-led giant or privately held.

In June 2026, Apollo-managed funds invested $1.25 billion for approximately 13% of McKesson Medical-Surgical, implying an enterprise value of about $13 billion; McKesson retained control and continues consolidating the business.[13] This creates both public exposure through MCK and private exposure through Apollo funds.

5. How the money works

Distribution is a spread business. The owner buys a product from a manufacturer, adds a modest markup, and delivers it — and everything hinges on keeping the cost of warehousing, delivering, and financing inventory below that markup. The metrics that matter are not the ones used for manufacturers or providers:

• Gross margin. Thin, and it varies sharply by channel. Bulk commodity distribution to hospitals runs at low margins (often mid-single digits to low double digits), because products are standardized and buyers negotiate hard. Value-added distribution to small dental, physician, and vet practices carries higher gross margins (roughly the mid-20s to low-30s percent) because it bundles equipment, consumables, software, service, and hand-holding for fragmented small customers.[18][19]
• Operating margin. Razor thin at the enterprise-distribution end — Cardinal's fiscal 2025 GMPD segment-profit margin was approximately 1.1%.[11] The business is a game of pennies multiplied by enormous volume. By contrast, Medline's 2025 adjusted EBITDA margin of 12.2% reflects its much larger owned-brand, manufacturing and vertically integrated profit pool — these are not directly comparable "distribution margins."[10]
• Inventory turns and working capital. Distributors sink cash into inventory and receivables. Turning inventory quickly and collecting from customers faster than they pay suppliers (favorable "days" math) is how a low-margin distributor generates cash and return on invested capital. Medline's 2025 filing illustrates the working-capital burden: higher receivables consumed $355 million of cash and higher inventories (including tariff effects) consumed $264 million; net capital expenditures were $447 million, including distribution-center automation and manufacturing investment.[10]
• Private-label / own-brand penetration. The single biggest margin lever. Medline and Cardinal Health manufacture their own products and sell them through their own distribution, capturing the manufacturer's margin on top of the distributor's. Higher own-brand mix is the main way a med-surg distributor escapes commodity economics. Medline manufactures approximately one-third of its Medline-brand products.[10]
• Value-added services. Logistics programs (just-in-time delivery, surgical kitting, inventory management), equipment servicing, financing, and technology (practice-management and e-commerce platforms) add stickier, higher-margin revenue and lock customers in.

There are effectively three business models under one code. (1) Acute-care med-surg — enormous volume, ultra-thin margins, contracts negotiated through purchasing alliances; you win with scale, logistics, and own-brand product. (2) Value-added specialty distribution to dental, physician, and veterinary practices — higher margins, more service and software, a large sales force selling to thousands of small independent customers. (3) Home medical equipment / "patient direct" — selling directly to patients and billing insurers, which behaves more like a health care provider than a distributor because revenue depends on reimbursement. All three sit inside the $311.5 billion figure.

6. What drives demand

• Overall health care utilization. U.S. national health expenditure reached about $4.9 trillion in 2023, or 17.6% of GDP (roughly $14,570 per person), growing 7.5% that year.[20] CMS projects national health expenditures to grow by an average 5.4% annually from 2025 through 2034, versus 4.1% nominal GDP growth, with health spending rising from 18.0% of GDP in 2024 to 20.6% in 2034.[20] Supplies volume broadly tracks this. Medical-and-surgical supply costs alone rose from about $40 billion to $57 billion between 2020 and 2025 — roughly 8% a year.[21]
• Aging demographics. The population age 65 and older reached 61.2 million in 2024, or 18.0% of the U.S. population, after growing 3.1% during that year.[22] Americans 55 and older are about 30% of the population but account for roughly 57% of health spending; the 65+ group spends about five times as much per person as children.[20][21] The aging Baby Boom is a durable multi-decade tailwind for procedure and supply volume.
• Surgical and procedure volume. About 1 in 9 Americans has a surgical procedure each year, and surgical care is nearly a third of health spending — each procedure consumes disposable supplies and instruments.[21]
• Site-of-care shift to outpatient. Procedures are migrating from hospitals to ambulatory surgery centers, physician offices, and the home. That reshuffles which distributors win (physician-office and home-care distribution grows faster) but keeps aggregate supply demand rising. In HIDA's 2025 panel data, sales increased 5.1% to hospitals, 2.3% to physician practices, 9.3% to home care, and 12.6% to treatment centers.[9]
• New products and technology. New devices, single-use disposables replacing reusables (infection control), and premium "physician-preference" items raise the dollar value flowing through distribution.
• Dental and veterinary cycles. The dental sub-market grows around 5–6% a year and is somewhat more discretionary (elective procedures dip in downturns), which is why dental-heavy distributors are a touch more cyclical than hospital-focused ones.[23]

Baseline demand is less cyclical than most durable-goods distribution because gloves, syringes, dressings and other consumables follow patient encounters. It is not immune to cycles. Dental and hospital capital equipment depends on budgets, credit and interest rates; elective procedures fluctuate; respiratory seasons affect product mix; and pandemics can create abrupt shortages followed by inventory destocking and price collapse. Medline states that illness patterns, elective-procedure timing and customer spending historically make its fourth quarter seasonally stronger.[10]

7. Regulation

• FDA oversight of the products. The U.S. Food and Drug Administration (FDA) regulates medical devices; distributors must handle products in line with those rules, manage recalls, and maintain traceability. The FDA's Unique Device Identification (UDI) system (final rule 2013) requires most devices to carry a machine-readable identifier registered in the FDA's Global Unique Device Identification Database (GUDID), which flows through the distribution chain.[24] Pure domestic wholesale distributors are not automatically required to register and list with FDA merely because they distribute devices, but initial importers, manufacturers, relabelers, repackagers and kit assemblers generally have additional obligations.[25] Vertically integrated distributors therefore face substantially more compliance exposure than a pure merchant.
• Postmarket requirements. Once devices are on the market, firms involved in distribution face requirements involving tracking, records, complaints, recalls and safety notifications. FDA can order a cease-distribution and notification process where a device presents a probability of serious adverse consequences or death.[26]
• Not the drug supply-chain rules. The Drug Supply Chain Security Act (DSCSA) — the track-and-trace regime with serialization requirements — applies to pharmaceuticals (NAICS 424210), not to most medical devices and supplies. It's a common point of confusion; device distributors generally live under FDA device rules, not DSCSA.[24]
• State licensing. Wholesale distributors of medical devices and home medical equipment need state licenses, and durable-medical-equipment suppliers that bill Medicare/Medicaid face federal enrollment, accreditation, and competitive-bidding rules.
• Reimbursement policy (indirect but powerful). For the home-medical and provider-facing parts of the business, what the Centers for Medicare & Medicaid Services (CMS) and private payers agree to pay sets the ceiling on prices and volumes. Distributors don't set reimbursement, but their customers' economics — and therefore purchasing budgets — depend on it.
• Trade and tariffs. Because so many commodity supplies (gloves, syringes, needles, masks) are made in China, U.S. Section 301 tariffs directly hit distributor costs. Tariffs on syringes and needles rose to 100% in 2024; rubber medical gloves are scheduled to reach 50% in 2025 and 100% in 2026; certain respirators and masks moved to 25% and then 50%.[27] Medline disclosed an approximately $290 million adverse impact to 2025 pretax income from tariffs and tariff developments and estimated a further approximately $200 million incremental impact for 2026 based on tariffs in effect at year-end 2025.[10] Hospitals and distributors have been actively managing the fallout — often shifting sourcing to other low-cost countries rather than reshoring to the U.S., because supply margins are too thin to support domestic production.[27][28]

8. Competitive dynamics and consolidation

The whole-industry statistics say "fragmented" (top-4 share under 24%, HHI 274),[2] but competition actually plays out inside distinct channels that are far more concentrated:

• Hospital / acute-care med-surg: an oligopoly of Medline, McKesson Medical-Surgical, Cardinal Health, and Concordance. Scale, national logistics networks, and own-brand manufacturing are the moats.
• Dental: a duopoly of Henry Schein and Patterson.
• Everything else: thousands of regional and single-specialty distributors serving the long tail — the source of the industry's low overall concentration.

Group purchasing organizations (GPOs) are the invisible hand over hospital purchasing. More than 95% of U.S. hospitals buy through GPOs, which pool member demand to negotiate prices; the three largest — Vizient, HealthTrust, and Premier — represent over 75% of the market, and GPOs are estimated to save hospitals roughly 10–18% on purchases.[29][30] GPOs set the contracts distributors must win to reach hospital customers, which compresses distributor margins and rewards scale.

A consolidation wave crested in 2025. Three landmark moves reshaped the public landscape in a single year: Patterson was taken private by Patient Square Capital for about $4.1 billion (April 2025);[14] Owens & Minor sold its Products & Healthcare Services (med-surg distribution) segment to private-equity firm Platinum Equity for $375 million (completed December 2025), exiting distribution to focus on home medical equipment;[15] and Medline completed the year's largest IPO, raising about $6.26 billion and reaching a market value above $50 billion on its debut.[31][32] The through-line: private equity is a dominant force, scale is consolidating, and the number of clean public distribution plays actually shrank even as the sector's biggest name (Medline) arrived on public markets.

9. Risks

• Margin compression. The core risk of any low-margin distributor. GPO leverage, customer consolidation (bigger hospital systems negotiate harder), and commodity pricing keep steady downward pressure on the spread.
• Tariffs and supply-chain shocks. Heavy reliance on Chinese-made commodities makes costs hostage to trade policy; distributors can pass some through, but existing fixed-price contracts mean they eat losses in the interim.[27][28] Medline's ~$290 million tariff hit to 2025 pretax income, with another ~$200 million expected in 2026, illustrates the scale of exposure.[10] The COVID-19 era showed how fast shortages and price spikes can hit.
• Customer concentration and disintermediation. Large health systems and manufacturers can bypass distributors (buy direct) or squeeze fees. Amazon and other e-commerce entrants nibble at the low end.
• Working-capital and rate sensitivity. Inventory- and receivables-heavy balance sheets mean higher interest rates raise the cost of carrying the very inventory the business is built on.
• Reimbursement and utilization. Cuts to Medicare/Medicaid payment, or a downturn in elective procedures (especially in dental), reduce customers' purchasing.
• Regulatory and product-liability exposure. Recalls, FDA actions, and quality failures create cost and reputational risk; the sector has also faced legal scrutiny (the diversified distributors carried large opioid-litigation liabilities on the pharma side, a reminder of how distribution can attract liability). Other material risks include counterfeit or gray-market product, sterilization constraints, single-source suppliers, expired or obsolete inventory, and cyberattacks on ordering and warehouse systems.
• Cyclicality where you'd least expect it. The industry is defensive overall, but the value-added/dental and capital-equipment ends are more discretionary and can soften when practices delay big-ticket purchases.

10. How to invest and the outlook

Public-market routes.

• Pure-ish plays: Medline (Nasdaq: MDLN) is now the largest listed pure medical-supply company after its December 2025 IPO, reporting $28.4 billion in 2025 net sales, $1.16 billion of net income (4.1% net margin), and $3.5 billion of adjusted EBITDA (12.2% margin).[10] Henry Schein (Nasdaq: HSIC) is the main listed dental-and-medical distributor.[12] Note Medline's post-IPO share float is limited by an insider lock-up into mid-2026, and private-equity owners (Blackstone, Carlyle, Hellman & Friedman) remain large holders.[31]
• Diversified exposure: Cardinal Health (NYSE: CAH), McKesson (NYSE: MCK), and Cencora (NYSE: COR) give you medical-distribution segments wrapped inside much larger pharmaceutical-distribution businesses — you're buying the whole company, not the med-surg slice.[7][11]
• Adjacent: Premier (Nasdaq: PINC) offers exposure to the GPO/purchasing side rather than distribution itself, and Accendra Health (NYSE: ACH) — the renamed former Owens & Minor — is now essentially a home-medical-equipment company with a 5% retained interest in the divested distribution business.[15][16]
• Because these are low-margin, capital-intensive businesses, the relevant valuation lens is cash generation and returns on capital rather than growth multiples; dividends exist at some names (e.g., Cardinal Health) but this is not primarily a yield sector.

Private-market routes. This is where much of the action is. Private equity owns Patterson (Patient Square Capital) and the former Owens & Minor distribution business (Platinum Equity), and the long tail of regional and specialty distributors is a steady source of roll-up and buyout opportunities.[14][15] Private and lower-middle-market investors participate through direct ownership of regional distributors, specialty (orthopedic, wound-care, lab) distribution niches, and home-medical-equipment providers — businesses valued on cash flow, route density, and customer stickiness rather than public multiples. The investment thesis usually rests on route density, procurement leverage, private-label penetration, warehouse automation, specialty-category expansion and consolidation. The corresponding diligence burden is unusually operational: customer and GPO contracts, supplier rebates, inventory aging, fill rates, freight terms, cybersecurity, FDA role classification and working-capital requirements matter more than headline revenue growth.

Near-term drivers and outlook (forward-looking). The demand backdrop is durable: an aging population, rising procedure volumes, and health spending growing faster than GDP should keep supply volumes climbing for years.[20][21] The tension is on margins — tariffs on Chinese-made commodities are a live 2025–2026 cost headwind,[27] GPO-driven price pressure is structural, and interest costs weigh on inventory-heavy balance sheets. The likely winners are the scaled distributors that manufacture their own products (own-brand margin), run the most efficient logistics, and layer on technology and services; the likely losers are undifferentiated commodity middlemen. For public investors, this is a defensive, cash-generative corner of health care with modest growth and thin margins; for private investors, it's a consolidating, service-differentiated space where operational excellence and buy-and-build strategies do the heavy lifting.

Common misconceptions. The most frequent errors are to call this a manufacturing industry; to treat Census wholesale receipts as medical-device end-market spending; to equate HIDA's narrower $61 billion 2025 channel measure with the complete NAICS market; or to compare consolidated company revenue with establishment-based Census data. Ownership descriptions also become stale quickly: Medline is public, Patterson and the Owens & Minor distribution business are private, and McKesson Medical-Surgical remains controlled and consolidated by McKesson despite Apollo's minority investment.[13]

---

Sources

1. U.S. Census Bureau, NAICS 423450 Definition, 2022. https://www.census.gov/naics/?chart=2022&details=423450&input=423450
2. U.S. Census Bureau, 2022 Economic Census — Concentration by Largest Firms (NAICS 423450), 2022 (industry sales/receipts, firm count, CR4/CR8/CR20/CR50, HHI). https://www.census.gov/programs-surveys/economic-census.html
3. U.S. Census Bureau, County Business Patterns 2023 (NAICS 423450), 2023 (establishments, employment, annual payroll). https://www.census.gov/programs-surveys/cbp.html
4. Health Industry Distributors Association, "Majority of Hospital Systems Utilize Commercial Distribution," 2024 (~90% of hospitals use commercial distributors). https://www.hida.org/KnowledgeCenter/KnowledgeCenter/articles/majority-hospital-systems-utilize-commercial-distribution.aspx
5. Health Industry Distributors Association, "Healthcare Distribution by the Numbers," 2024 (1.4M products, 7,300 manufacturers, 500+ DCs). https://www.hida.org/distribution/resources/infographics/healthcare-distribution-by-the-numbers.aspx
6. Owens & Minor, Inc., 2024 Form 10-K, 2025 (contract structures, cost-plus and activity-based fee models). https://www.sec.gov/Archives/edgar/data/75252/000155837025001940/omi-20241231x10k.htm
7. IntuitionLabs, "US Drug Wholesalers: How McKesson, Cencora & Cardinal Control 90%+ of Distribution," 2025 (Big Three concentration; med-surg vs. pharma split). https://intuitionlabs.ai/articles/drug-wholesaler-market-concentration
8. U.S. Small Business Administration, Table of Size Standards (NAICS 423450 — 200 employees), 2023. https://www.sba.gov/document/support-table-size-standards
9. Health Industry Distributors Association, "Medical Products Sales Through Distribution Reach $61B in 2025," 2025 ($57.5B in 2023, $61B in 2025; channel growth rates). https://www.hida.org/KnowledgeCenter/KnowledgeCenter/articles/medical-products-sales-distribution-reach-61b-2025.aspx
10. Medline Inc., 2025 Form 10-K, 2026 (net sales $28.4B, net income $1.16B, 4.1% net margin, $3.5B adjusted EBITDA at 12.2% margin; ~one-third self-manufactured; tariff impacts; working capital; seasonality). https://www.sec.gov/Archives/edgar/data/2046386/000204638626000009/mdln-20251231.htm
11. Cardinal Health, Fiscal Year 2025 Form 10-K, 2025 (Global Medical Products and Distribution segment ~$12.6B revenue, $135M segment profit, ~1.1% margin). https://www.sec.gov/Archives/edgar/data/721371/000072137125000079/cah-20250630.htm
12. Henry Schein, Inc., 2025 Form 10-K, 2026 (Global Distribution segment $11.1B: $6.9B dental, $4.3B medical). https://www.sec.gov/Archives/edgar/data/1000228/000100022826000013/hsic-20251227.htm
13. McKesson Corporation, "McKesson Closes Strategic Investment with Apollo Funds for Minority Interest in Medical-Surgical Solutions," June 2026 ($1.25B for ~13% stake, ~$13B implied EV). https://investor.mckesson.com/news/financial-news/2026/McKesson-Closes-Strategic-Investment-with-Apollo-Funds-for-Minority-Interest-in-Medical-Surgical-Solutions/default.aspx
14. Latham & Watkins, "Patient Square Capital's Completed US$4.1 Billion Acquisition of Patterson Companies," 2025. https://www.lw.com/en/news/2025/04/latham-advises-on-patient-square-capital-completed-us4-1-billion-acquisition-of-patterson-companies
15. Owens & Minor, Inc., "Completes Sale of Products & Healthcare Services Business to Platinum Equity," Business Wire, December 2025 (FY2024 revenue ~$10.7B; $375M price). https://www.businesswire.com/news/home/20251231395792/en/Owens-Minor-Inc.-Completes-Sale-of-Products-Healthcare-Services-Business-to-Platinum-Equity
16. Accendra Health (formerly Owens & Minor), Form 8-K, December 2025 (renamed ACH; retained 5% interest in divested business). https://www.sec.gov/Archives/edgar/data/75252/000110465925122553/omi-20251216x8k.htm
17. Concordance Healthcare Solutions, "About Concordance," 2024 (company history). https://www.concordancehealthcare.com/about-concordance
18. Umbrex, "How the Medical Device Industry Works," 2024 (distributor economics, thin per-unit margins). https://umbrex.com/resources/how-industries-work/healthcare-and-life-sciences/how-the-medical-device-industry-works/
19. CSIMarket, "Medical Equipment & Supplies Industry Profitability Ratios & Margins," Q1 2026 (industry gross/operating margin ranges). https://csimarket.com/Industry/industry_Profitability_Ratios.php?ind=804
20. Centers for Medicare & Medicaid Services, National Health Expenditures Fact Sheet, 2024 ($4.9T in 2023, 17.6% of GDP, $14,570/person, 7.5% growth; 5.4% projected annual growth through 2034; age-of-spending distribution). https://www.cms.gov/data-research/statistics-trends-and-reports/national-health-expenditure-data/nhe-fact-sheet
21. Definitive Healthcare, "Annual Hospital Medical Supply Cost Changes," 2026 (med/surg supply costs $40B→$57B, 2020–2025; surgical volume; aging spend). https://www.definitivehc.com/resources/healthcare-insights/changes-in-supply-costs-year-to-year
22. U.S. Census Bureau, "Older Adults Continue to Outnumber Children in the U.S.," 2025 (65+ population 61.2M, 18.0% of total, 3.1% growth in 2024). https://www.census.gov/newsroom/press-releases/2025/older-adults-outnumber-children.html
23. Grand View Research, "Dental Equipment Market Size, Share & Trends Report," 2024 (dental sub-market growth ~5–6%). https://www.grandviewresearch.com/industry-analysis/dental-equipment-market
24. U.S. Food and Drug Administration, "Unique Device Identification System (UDI System)," 2013 rule / current (device regulation, GUDID; DSCSA applies to drugs, not devices). https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/unique-device-identification-system-udi-system
25. U.S. Food and Drug Administration, "Who Must Register, List, and Pay the Fee," 2024 (registration requirements by role). https://www.fda.gov/medical-devices/device-registration-and-listing/who-must-register-list-and-pay-fee
26. U.S. Food and Drug Administration, "Postmarket Requirements (Devices)," 2024 (tracking, records, recalls, safety notifications). https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/postmarket-requirements-devices
27. UNC Center for the Business of Health (CBOH), "Tariffs on Medical Devices and Supplies: Healthcare Cost Implications," 2025 (Section 301 tariff schedule on syringes, gloves, PPE). https://cboh.unc.edu/publication/tariffs-on-medical-devices-and-supplies-healthcare-cost-implications/
28. Axios, "Hospitals begin to grapple with tariff fallout," May 2025 (contract exposure; sourcing shifts vs. reshoring). https://www.axios.com/2025/05/01/hospitals-struggle-tariff-impacts
29. Vizient, Inc., "Hospitals and patients nationwide benefit from Group Purchasing Organization collaboration," 2022 (>95% of hospitals use GPOs; 10–18% savings). https://www.vizientinc.com/insights/all/2022/hospitals-and-patients-nationwide-benefit-from-group-purchasing-organization-collaboration
30. Definitive Healthcare, "Top 10 GPOs by Staffed Beds in U.S. Hospitals," 2024 (Vizient, HealthTrust, Premier = ~75%+ of market). https://www.definitivehc.com/blog/top-10-gpos-by-staffed-beds
31. CNBC, "Medline debuts on Nasdaq after biggest IPO of 2025," December 2025 (IPO $6.26B, valuation, ownership). https://www.cnbc.com/2025/12/17/medline-debuts-nasdaq-biggest-ipo-2025.html
32. FierceBiotech, "Medline makes Nasdaq debut, raising $6.26B in year's largest IPO," December 2025. https://www.fiercebiotech.com/medtech/medline-makes-nasdaq-debut-raising-626b-years-largest-ipo